Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&A Deals, Week Ending November 22, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Aerie Pharmaceuticals, Inc. Avizorex Pharma, S.L $10,000,000 Advent International Bharat Serums and Vaccines Limited N/A Alkermes, Inc. Rodin Therapeutics, Inc. $100,000,000 Appili Therapeutics Inc. Novel antifungal drug ATI-2307 N/A eHealth... Read More »
Lumenis Finally Finds a Buyer
After a four-year partnership, XIO Group has finally sold Lumenis. CVC Capital Partners and FountainVest Partners came incredibly close to purchasing the medical device firm late last year for an estimated $950 million, according to reports in Calcalist, but the deal was never finalized. Fast forward to the present day, and Baring Private Equity Asia (BPEA) has emerged as the buyer, spending $1 billion for the Israeli firm. Lumenis provides specialty minimally invasive medical devices in the fields of aesthetics, urology, ophthalmology, ENT, and gynecology. The company has a presence in more than 100 countries. XIO Group acquired Lumenis in 2015 for $510 million, or $14 a share, when the... Read More »
LGC Gets New Owners After Multi-Billion Deal
Cinven and Astorg have joined forces to purchase LGC Group from KKR (NYSE: KKR). The two global private equity firms spent $3.88 billion (£3 billion) for the firm, according to sources cited in Private Equity News. LGC provides a range of measurement tools, proficiency testing schemes, supply chain assurance standards, and specialty genomics reagents to the life sciences industry. According to our Deal Search Online database, this is the largest deal in the Laboratories, MRI and Dialysis sector, based on disclosed prices in 2019. This deal ends a four-year partnership that started in December 2015 when KKR acquired LGC for $989 million. At the time, LGC was a portfolio company of... Read More »U.S. Hospital Deals and Trends, YTD 2019
Winding down to the end of 2019, it’s a good time to take stock of this year’s U.S. hospital M&A market. In mid-November, we have 70 transactions on the books, up 16% compared with the same period in 2018. But 2019 M&A activity has taken a decidedly different path from the deals of 2018. One striking statistic: Just half the number of beds have traded hands in 2019. By this time in 2018, the bed-count in target hospitals was 25,309. In 2019, there are only 12,901 (-49%). In 2018, a few major systems changed hands, which pushed up the bed total. The largest was Apollo Global Management’s $5.6 billion take-private deal for LifePoint Health (formerly NASDAQ: LPNT),... Read More »
Phenomics Health Adds Clinical Assessment Capabilities
Making sure patients with multiple chronic conditions aren’t over- or under-dosed with medications can be a fraught process. Phenomics Health, based in Ann Arbor, Michigan, has been working on the genomics side of the problem. Its recent acquisition of Precera Bioscience’s patented portfolio of pharmacometabolomic technology adds capabilities to provide a more complete view of patients’ potential and actual response to medications than is currently available. Phenomics Health is a bioinformatics platform-based precision medicine company that uses artificial intelligence and machine learning to translate advanced genetic, epigenetic, multi-omics and health data into novel... Read More »
Health Care M&A Deals, Week Ending November 15, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Community Health Network Fairbanks N/A Discovery Behavioral Health Authentic Recovery Center N/A Biotechnology Acquirer Target Price Mesa Laboratories, Inc. Gyros Protein Technologies Holding AB $180,000,000 Foamix Pharmaceuticals... Read More »
PE Firms Trade WIRB-Copernicus for $3 Billion
Leonard Green & Partners, L.P won the auction to acquire WIRB-Copernicus Group (WCG) from Arsenal Capital Partners for $3 billion. The purchase value was originally reported in PE Hub Buyouts. WCG is a clinical services organization that enables biopharmaceutical companies, contract research organizations and institutions to accelerate the delivery of new treatments and therapies to patients. Arsenal will retain a stake in WCG. It acquired the company in March 2012 and led its recapitalization in August 2016 alongside other investors, including MSD Partners, the family office of Michael Dell. WCG has an estimated EBITDA of $175 million for 2019. WCG has been relatively quiet on the... Read More »
Welltower Shuffles Medical Office Building Portfolio
Welltower Inc. (NYSE: WELL), one of the largest diversified healthcare REITs, is mixing up its medical office building portfolio. Although Welltower is incredibly active in the Long-Term Care sector with its post-acute care facility portfolio, its MOB portfolio is worth highlighting. So far this year, the company has announced $3.5 billion worth of outpatient medical acquisitions. The most recent acquisition involves the purchase of a 29 Class-A medical office portfolio from Hammes Partners for $787 million. The portfolio totals 1.5 million square feet and has an average age of 10 years, with 12 years of weighted average lease term and 2.2% average annual rent increases. The... Read More »
Biogen Eyes Two Ophthalmic Biosimilars
Boston-based Biogen Inc. (NASDAQ: BIIB) has announced a “proposed transaction” with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 referencing Eylea®, in major markets worldwide, including the United States, Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for Samsung Bioepis’ anti-TNF portfolio, including Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), in China. Biogen will also acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti-TNF portfolio in Europe.... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
